Granules India Limited (BOM:532482)
799.95
+5.45 (0.69%)
At close: Nov 6, 2026
Granules India Revenue
Granules India had revenue of 15.71B INR in the quarter ending September 30, 2026, with 21.10% growth. This brings the company's total for the last twelve months to 58.93B, up 21.70% year-over-year. In the fiscal year ending March 31, 2026, Granules India had annual revenue of 53.66B with 19.73% growth. That makes Granules India the 10,009th largest company in the world by revenue and 422nd in India.
Revenue (ttm)
58.93B
Revenue Growth
+21.70%
P/S Ratio
3.36
Revenue / Employee
13.69M
Employees
4,306
Market Cap
198.23B
Revenue by Geography
- Outside India 51.44B 95.9%
- India 2.22B 4.1%
Fiscal year ended Mar 31, 2026 See the full Granules India breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 53.66B | 8.84B | 19.73% |
| Mar 31, 2025 | 44.82B | -247.59M | -0.55% |
| Mar 31, 2024 | 45.06B | -55.50M | -0.12% |
| Mar 31, 2023 | 45.12B | 7.47B | 19.84% |
| Mar 31, 2022 | 37.65B | 5.27B | 16.29% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Jubilant Pharmova | 86.08B |
| Abbott India | 70.04B |
| GlaxoSmithKline Pharmaceuticals | 41.98B |
| J. B. Chemicals & Pharmaceuticals | 41.48B |
| Viyash Scientific | 35.75B |
| AstraZeneca Pharma India | 24.32B |
| FDC Limited | 22.89B |
| Caplin Point Laboratories | 22.87B |
Granules India News
- 4 days ago - Granules India Q2 net profit rises 39% - The Times of India
- 4 days ago - Granules India Transcript: Q2 26/27 - Transcripts
- 4 days ago - Granules India Quarterly report: Q2 2027 - Filings
- 4 days ago - Granules India Slides: Q2 2027 - Filings
- 4 weeks ago - Granules India plans ₹2,000 crore investment to drive growth in complex generics, oncology, and peptide CDMO - The Times of India
- 7 weeks ago - Hyderabad Granules promoter sells 7% stake to raise 1.5k crore - The Times of India
- 3 months ago - Granules India Transcript: Q1 26/27 - Transcripts
- 3 months ago - Granules India Quarterly report: Q1 2027 - Filings